AACR22: Af­ter Fer­Gene blowup, a start­up touts even bet­ter blad­der can­cer gene ther­a­py re­sults in tiny study

A pri­vate Cal­i­for­nia biotech is rais­ing some eye­brows on the fi­nal day of AACR22 as it re­port­ed in­ter­im da­ta for its ex­per­i­men­tal drug in com­bi­na­tion with Keytru­da.

Look­ing at 18 pa­tients with non-mus­cle-in­va­sive blad­der can­cer who are un­re­spon­sive to bacil­lus Cal­mette-Guérin (an FDA-ap­proved agent for blad­der car­ci­no­mas), CG On­col­o­gy found that 16 of the 18 achieved a com­plete re­sponse af­ter just three months. On top of this, 13 main­tained their re­sponse through six months, nine through nine months and eight af­ter a year — the study’s pri­ma­ry end­point.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER